CHRONIC LYMPHOCYTIC LEUKEMIA

This study tests whether a new COVID-19 booster vaccine (GEO-CM04S1) works better than the standard mRNA booster for people with chronic lymphocytic leukemia (CLL). About 80 adults with CLL who have already had at least two mRNA COVID shots will receive either the new vaccine or …

This study tests whether extra COVID-19 vaccine doses can improve protection for people with weakened immune systems, including those with HIV, organ transplants, or blood cancers. About 960 participants will receive different booster schedules to see which works best. The goal i…

This study tests a vaccine designed to protect people who have had a stem cell transplant from a common virus called CMV. The virus can cause serious illness in those with weak immune systems. The vaccine uses a harmless virus to teach the body to fight CMV, aiming to reduce infe…

This early-phase study tests NKX019, a therapy made from donor immune cells (natural killer cells) that are engineered to find and attack cancer cells. It is for adults with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to other treatments…

This study tests a two-step treatment plan for young adults (up to age 65) with high-risk chronic lymphocytic leukemia (CLL) who have not had prior therapy. First, patients receive a combination of venetoclax and obinutuzumab. Then, based on whether any cancer cells remain, they …

This study tests a drug called ACP-196 (acalabrutinib) in 60 adults with chronic lymphocytic leukemia (CLL) whose cancer returned or didn't respond to treatment and who had to stop ibrutinib because of side effects. The main goal is to see how many patients' tumors shrink or disa…

This study tests whether adding a new targeted drug, pirtobrutinib, to the standard combination of venetoclax and rituximab helps people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) live longer without their cancer getting worse. About 600 adults wh…

This phase 2 study tests whether adding sonrotoclax to the standard drug zanubrutinib works better than zanubrutinib alone for adults with untreated chronic lymphocytic leukemia (CLL). About 94 participants will receive either the combination or the single drug. The goal is to se…

This study tests whether combining two drugs, ibrutinib and obinutuzumab, is safe and effective for people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to treatment. About 54 adults with CLL will receive different doses of the drug pair. The ma…

This study tested a combination of two targeted drugs, venetoclax and ibrutinib, in 234 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal was to see how well the drugs control the cancer, especially in patients whose disease came back or had h…

This study tested a new drug called acalabrutinib against two standard treatments for people with chronic lymphocytic leukemia (CLL) that had come back or stopped responding to prior therapy. About 310 adults took part. The main goal was to see if acalabrutinib could delay cancer…

This study tests a combination of three drugs (obinutuzumab, ibrutinib, and venetoclax) in people with chronic lymphocytic leukemia (CLL) that has come back, not responded to treatment, or is newly diagnosed. The goal is to find the best dose and see how well the drugs work toget…

This phase 3 trial tests whether adding venetoclax to the standard combination of ibrutinib and obinutuzumab helps younger patients with untreated chronic lymphocytic leukemia (CLL) live longer without their cancer worsening. About 720 participants will receive either the two-dru…

This study tests a new treatment called rapcabtagene autoleucel (YTB323) for adults with several types of blood cancer, including chronic lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. The treatment uses a patien…

This study tests whether adding venetoclax to ibrutinib can eliminate genetic mutations that make chronic lymphocytic leukemia (CLL) resistant to ibrutinib. About 28 adults with CLL who already have these resistance mutations will receive both drugs for 12 cycles. The goal is to …

This study tests a two-drug combination (ixazomib and rituximab) in people with slow-growing B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with different types of this lymphoma are taking part.

This study looks at how long 151 adults with chronic lymphocytic leukemia (CLL) in Italy stay on the drug acalabrutinib (Calquence) and why they might stop. Researchers are collecting data from routine care to see how the drug works outside of clinical trials. The goal is to bett…

This study tests a combination of two drugs, duvelisib and venetoclax, in people with relapsed or hard-to-treat chronic lymphocytic leukemia (CLL) or Richter's Syndrome. The goal is to see if the combo can shrink or control the cancer. About 55 adults who have already tried at le…

This study tests whether adding special 'veto' cells to a stem cell transplant can help donor cells grow in the body without causing severe graft-versus-host disease (GVHD). It includes 16 people aged 12-75 with various blood cancers or bone marrow failure. The veto cells are tre…

This study tests a combination of three drugs—acalabrutinib, umbralisib, and ublituximab—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal is to see how many patients achieve complete remission after 24 cycles of treatment. The trial includ…

This study tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor in 21 people with various blood cancers like leukemia and lymphoma. The goal was to see if this approach could help patients survive and recover without severe side effects.…

This study tests an experimental radioactive drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphoma) that have come back or not responded to standard treatments. The drug is designed to target and kill…

This study tests a new drug, LOXO-305, against two standard treatment combinations for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has already been treated with a BTK inhibitor. About 238 participants will be randomly assigned t…

This study tests a combination of two drugs, pirtobrutinib and venetoclax, for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The treatment length is guided by a sensitive blood test that looks for leftover cancer cells (minimal resi…

This study tests whether the drug lenalidomide, combined with a vaccine, can help the immune system fight early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in people with high-risk genetic features. Lenalidomide works by cutting off blood supply t…

This study tested a combination of two drugs, ibrutinib and fludarabine, in 29 people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Participants took ibrutinib daily and received fludarabine for a short time. The goal was to see how many p…

This study tested whether a combination of ibrutinib (a targeted pill) plus rituximab works better than standard chemotherapy (FCR) for younger patients with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 529 people took part. The main goa…

This study tests a vaccine called Triplex to see if it can prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV is usually harmless but can be dangerous for people with weakened immune systems. The vaccine uses harmless pieces of CMV DNA…

This study tests a combination of two drugs, venetoclax and rituximab, in people whose chronic lymphocytic leukemia (CLL) has come back or stopped responding to previous treatments. The goal is to see how well the combination works at shrinking or eliminating cancer. About 25 adu…

This study tests a drug called MK-2140 (zilovertamab vedotin) in people with certain B-cell blood cancers that have come back or not responded to other treatments. About 189 adults with mantle cell lymphoma, Richter's transformation lymphoma, follicular lymphoma, or chronic lymph…

This study tests whether adding a newer drug (venetoclax) to the usual two-drug treatment (ibrutinib + obinutuzumab) helps older adults with untreated chronic lymphocytic leukemia (CLL) stay cancer-free longer. About 465 people aged 65+ will be randomly assigned to receive either…

This study tests a combination of two drugs, tafasitamab and zanubrutinib, in people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if the combo can kill more cancer cells than either drug alone. About 26 adults wil…

This study compares a new oral targeted therapy, nemtabrutinib, against standard chemoimmunotherapy in 300 people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a specific genetic change (TP53 mutation). The main g…

This study tests whether adding cirmtuzumab to the standard drug venetoclax can eliminate remaining cancer cells in people with chronic lymphocytic leukemia (CLL). It involves 5 adults who still have detectable leukemia despite at least 12 months of venetoclax. The goal is to see…

This early-phase study tests an oral drug called APG-2575 in adults with relapsed or hard-to-treat chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). The main goal is to find a safe dose and check for side effects. About 74 participants will take the drug by mouth…

This study tests if people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) can safely stop taking acalabrutinib and obinutuzumab once their cancer responds well, instead of continuing treatment indefinitely. The goal is to reduce side effects and preve…

This early-stage study tests adding loncastuximab tesirine to the standard drug acalabrutinib for people with chronic lymphocytic leukemia (CLL). The main goal is to find the safest dose of the combination. Researchers will also check if the treatment can make cancer cells undete…

This early-phase study tests a new drug combination (ceralasertib plus acalabrutinib) in 12 people with high-risk chronic lymphocytic leukemia (CLL) that has come back or not responded to prior treatments. The main goal is to check safety and find the right dose. Participants mus…

This early-phase study tests whether giving healthy donor natural killer (NK) cells along with two drugs (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach/esophageal, or blood cancers. The NK cells are meant to attack cance…

This early-phase study tests a combination of two drugs, copanlisib and nivolumab, in people with certain types of blood cancer that have changed into a more aggressive form (Richter's transformation or transformed non-Hodgkin lymphoma). The goal is to find the best dose and see …

This early-phase study tests a new type of immune cell therapy (huCART19-IL18) for people with certain blood cancers that have come back or not responded to treatment. The therapy involves modifying a patient's own immune cells to better find and attack cancer cells. The main goa…

This study gives venetoclax to 165 people with blood cancers like leukemia and lymphoma who already benefited from the drug in earlier studies. The main goal is to track side effects and see how safe the drug is over a longer period. Participants must have tolerated the drug well…

This study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to lower the risk of graft-versus-host disease, a common complication. The goal is to see i…

This early-phase study tests an experimental drug called ABBV-453 in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to at least two prior treatments. The main goals are to check safety, find the right dose, a…

This study looks at whether giving vitamin D to cancer patients who are low in it can help them live longer without their disease getting worse. About 565 adults with certain lymphomas or leukemia will either get vitamin D or no extra vitamin D. The goal is to see if vitamin D re…

This early-phase trial tests a new treatment for people with B-cell cancers (like leukemia or lymphoma) that haven't improved with standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. Partici…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease. About 313 adults with various blood cancers…

This study tests a drug called acalabrutinib in people with chronic lymphocytic leukemia (CLL) who also have a type of anemia (AIHA) that came back or didn't get better with standard treatment. The drug works by blocking certain enzymes that help cancer cells grow. The main goal …

This early-stage study tests a new treatment called SC291 for people with certain types of blood cancers (non-Hodgkin lymphoma or chronic lymphocytic leukemia) that have come back or not responded to other treatments. SC291 is a type of immune cell therapy designed to find and at…

This phase 3 study tests whether zanubrutinib, a targeted oral drug, works better than the standard combination of bendamustine and rituximab for people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. About 590 participants who cannot receive…

This study tests whether adding the targeted drug ibrutinib to standard chemotherapy can completely clear chronic lymphocytic leukemia (CLL) from the bone marrow in younger, untreated patients. About 85 participants will receive the combination and be monitored for two years afte…

This study tests a new drug (IPI-145) added to a standard chemotherapy combination (FCR) for younger adults (ages 18-65) with untreated chronic lymphocytic leukemia (CLL). The goal is to see if the new combo is safe and can make the cancer disappear more completely, as measured b…

This early-phase trial tests a new treatment called FT819 for people with B-cell blood cancers (lymphoma, CLL, or B-ALL) that have not responded to standard therapies. The treatment uses specially engineered immune cells to target and attack cancer cells. The main goals are to fi…

This early-phase study tests a new drug called ABBV-525 in people with B-cell cancers like lymphoma and leukemia. The goal is to check safety and find the best dose. About 78 adults will take the drug by mouth at different dose levels over up to 64 months.

This study follows 192 adults with chronic lymphocytic leukemia (CLL) in Spain who started taking acalabrutinib as their first treatment or switched to it due to side effects from an older drug. Researchers will track how many patients stay on the therapy after 24 months and look…

This phase 3 study compares two oral medications, acalabrutinib and ibrutinib, in adults with high-risk chronic lymphocytic leukemia (CLL) who have already received at least one prior treatment. The goal is to see if acalabrutinib is as effective as ibrutinib at delaying cancer p…

This early-phase study tests a new approach for people with B-cell lymphoma or leukemia that has returned or not responded to standard therapy. Researchers take a patient's own immune cells (T cells), modify them in the lab to recognize and attack cancer cells carrying the CD19 p…

This study tests a combination of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab as a first treatment for people with chronic lymphocytic leukemia (CLL) who have a specific gene mutation (mutated IGHV) and no deletion in chromosome 17. The goal is to see if this drug …

This early-phase study tested a combination of two drugs, daratumumab and ibrutinib, in 15 people with untreated chronic lymphocytic leukemia (CLL). The goal was to see if the combination is safe and effective at controlling the disease. Participants received both drugs to target…

This study follows about 90 adults with chronic lymphocytic leukemia (CLL) who are taking the drug acalabrutinib as part of their normal care. Researchers will collect information from medical records to see how long patients live without their cancer getting worse and what side …

This study tests whether people with chronic lymphocytic leukemia (CLL) can safely start venetoclax faster than the usual 5-week schedule. About 40 patients with new or returning CLL will take venetoclax daily with a quicker dose increase. The goal is to see if this faster approa…

This study tests whether a daily pill called pirtobrutinib works better than the standard chemo-immunotherapy combination (bendamustine + rituximab) for people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have not yet been treated. About 309 participants wi…

This study tests different ways to start and increase the dose of sonrotoclax in adults with chronic lymphocytic leukemia (CLL). The main goal is to see if these new dosing schedules lower the risk of tumor lysis syndrome, a serious side effect. About 56 participants will be enro…

This study tests a new oral drug called ARQ 531 (nemtabrutinib) in about 190 people with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to prior therapy. The goal is to find the safest dose and see if the drug can shrink tumors. Participants…

This study looks at whether adding the drug venetoclax to standard BTKi therapy can help people with chronic lymphocytic leukemia (CLL) reach very deep remission. The goal is to allow patients to stop treatment for a period. About 118 adults who have been on BTKi therapy for at l…

This study tests a combination of three drugs—atezolizumab, obinutuzumab, and venetoclax—in about 50 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, or Richter syndrome that has returned or not responded to prior treatment. The goal is to see if the co…

This study tests a new drug called acalabrutinib for people with chronic lymphocytic leukemia (CLL) or related blood cancers. The goal is to see if the drug is safe and can shrink or control the cancer. Participants take the drug by mouth, and the study tracks side effects and ho…

This early-phase study tests a new type of immunotherapy called tri-specific CAR T-cells for people with B-cell lymphomas that have come back or not responded to treatment. The therapy is designed to target three different markers on cancer cells to improve effectiveness and redu…

This early-phase trial tests whether giving a CMV vaccine to stem cell donors can boost the recipient's immunity after transplant. About 34 blood cancer patients receiving donor stem cells are involved. The goal is to prevent CMV viremia, a common and serious viral infection, wit…

This study tests different programs to help people at high risk for cancer (such as those with BRCA or Lynch syndrome) or cancer survivors increase their physical activity and eat healthier. The goal is to see which program works best to improve waist size and overall health, whi…

This study tests whether the drug ruxolitinib (Jakafi) can help reduce severe fatigue in people with chronic lymphocytic leukemia (CLL). About 10 participants who have CLL but do not yet need standard treatment will take the drug and report their fatigue levels. The goal is to se…

This study tests whether exercise and weight management can reduce fatigue in people who have had chronic lymphocytic leukemia (CLL). About 30 adults aged 18-85 with CLL and low physical activity levels will take part. Participants will be randomly assigned to start the program r…

This study is not testing a new treatment. Instead, it will collect information from about 6,000 adults with chronic lymphocytic leukemia (CLL) in Russia to see how doctors currently manage the disease. Researchers will look at patient health records, genetic test results, and tr…

This study looks at how blood cancers and stem cell transplants affect muscle function in 144 patients. Researchers want to see if muscle health can help predict complications like infections, relapse, or survival. The goal is to better understand the role of muscle strength at k…

This study looks for a blood test that can tell which patients with chronic lymphocytic leukemia (CLL) or multiple myeloma are at higher risk for infections. Researchers will use advanced lab methods to analyze blood samples from 150 adults. The goal is to help doctors prevent in…

This study looks at how people with chronic lymphocytic leukemia (CLL) feel and function while taking different oral treatments. About 146 adults in Spain will fill out questionnaires about their symptoms, fatigue, and worries during routine doctor visits. The goal is to understa…

This study watches 350 people with chronic lymphocytic leukemia (CLL) who are taking the drug acalabrutinib as part of their normal care. Researchers want to see how long patients stay on the drug, why they stop, and how well it works outside of a strict research setting. The goa…

This study looks at 250 adults with chronic lymphocytic leukemia (CLL) in Romania who are taking the drug acalabrutinib as part of their normal care. Researchers want to see how long patients stay on the treatment and why they might stop. The goal is to understand how the drug wo…

This study follows people who previously received an experimental CAR-T cell therapy from AvenCell for cancers like lymphoma, leukemia, or prostate cancer. The goal is to track long-term side effects, including new cancers, nerve problems, or immune disorders. About 178 participa…

This study looks at people and families who may be more likely to develop blood or lymph node cancers, such as leukemia or lymphoma. Researchers want to learn about the genetic and environmental factors that raise cancer risk. Participants fill out health questionnaires and provi…

This study watches 50 adults with chronic lymphocytic leukemia who are starting certain drugs (acalabrutinib or zanabrutinib). These drugs can cause high blood pressure and irregular heartbeats. Participants will use wearable devices at home to track their heart rhythm and blood …

This study looked at the costs and quality-of-life benefits of three different drug combinations for older adults (65 and up) with chronic lymphocytic leukemia (CLL). Researchers compared a standard chemo-immunotherapy (bendamustine plus rituximab) with two newer ibrutinib-based …